The FDA’s drug approval database shows that the injectable product Trimethobenzamide Hydrochloride, marketed under the brand name TRIMETHOBENZAMIDE HYDROCHLORIDE with product number 001, has a marketing status of "Discontinued" under application number ANDA089094. The sponsor for this product is SoloPak.
The product is an injection dosage form containing 100 mg/mL of Trimethobenzamide Hydrochloride. No reference drug or reference standard is indicated. The discontinued status means the product is no longer marketed in the United States.
Regulatory UpdatesSep 19, 2026•1 min read
FDA Discontinues Trimethobenzamide Injection (ANDA 089094)
The FDA has listed the injectable Trimethobenzamide Hydrochloride (product 001) from sponsor SoloPak as discontinued under ANDA 089094.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating